SARS-CoV-2 is continuously evolving. The Omicron subvariant BA. 2.86, with> 30 mutations
in its spike (S) protein compared with its predecessor strain BA. 2, was expected to quickly …

Among the anti-Spike monoclonal antibodies (mAbs), the S-309 derivative sotrovimab was
the most successful in having the longest temporal window of clinical use, showing a high …

Abstract On September 12, 2023, CDC's Advisory Committee on Immunization Practices
recommended updated 2023–2024 (updated) COVID-19 vaccination with a monovalent …

The continuous evolution of SARS-CoV-2, particularly the emergence of BA. 2.86/JN. 1
lineage replacing XBB, necessitates re-evaluation of vaccine compositions 1–3. Here, we …

The JN. 1 variant (BA. 2.86. 1.1), arising from BA. 2.86. 1 with the S: L455S substitution,
showed increased fitness and outcompeted the previous dominant XBB lineage by the …

Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants - The Lancet
Infectious Diseases Skip to Main Content Skip to Main Menu Advertisement The Lancet …

We investigate JN. 1-derived subvariants SLip, FLiRT, and KP. 2 for neutralization by
antibodies in vaccinated individuals, severe acute respiratory syndrome coronavirus 2 …

Abstract SARS-CoV-2 JN. 1 with an additional L455S mutation on spike when compared
with its parental variant BA. 2.86 has outcompeted all earlier variants to become the …

Summary Background During the 2023 Danish COVID-19 vaccination campaign, an
updated monovalent mRNA vaccine targeting the SARS-CoV-2 omicron XBB. 1.5 subvariant …

The Omicron subvariants of SARS-CoV-2, especially for BA. 2.86 and JN. 1, have rapidly
spread across multiple countries, posing a significant threat in the ongoing COVID-19 …